PPN Facebook PPN Twitter PPN Instagram


Was your patient recently diagnosed with PANS/PANDAS?

Patients recently diagnosed with moderate to severe PANS (Pediatric Acute-onset Neuropsychiatric Syndrome) / PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections) may qualify to participate in a IVIG study.

The purpose of the study is to determine the sustainability of the reduction of the severity of symptoms in children treated with IVIG and to assess its efficacy in reducing functional impairment associated with PANS/PANDAS.

This is a randomized, double-blind, placebo-controlled superiority study spanning about 6 months. All participants will receive the study drug and placebo (no active ingredients). Help with study-related travel expenses will be provided.

Contact snehal.udavat@octapharma.com for more information.


6-17 years in age

Onset of initial PANS/PANDAS episode must not be more than seven months prior to first investigational medicinal product treatment. In patients with relapsing episodes, initial episode may not have been more than 12 months prior to Screening, must have fully resolved based on investigator’s judgment, and the recurrence must be less than six months prior to Screening

Moderate to severe PANS/PANDAS with prominent and stable obsessive-compulsive disorder symptoms

Do not have symptoms consistent with autism, schizophrenia, bipolar disorder, or any other psychotic disorder (unless psychotic symptoms have onset coincident with PANS/PANDAS).

For the full list of criteria and exclusions, please visit the clinical trial page. (Identifier: NCT04508530)

For more information about enrollment, please contact:

Snehal Udavat
Clinical operations at Octapharma USA, Inc.